CUV 1.61% $14.68 clinuvel pharmaceuticals limited

Ann: SCENESSE launched in Europe-CUV.AX, page-10

  1. 578 Posts.
    lightbulb Created with Sketch. 84
    Quite possibly cash flow positive AND profitable within a few quarters, with zero net debt.
    New regional approvals possible within a 12-18 month timeframe, and possible further indications a little bit after that.
    Finally it may all be lining up.
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.